Human tartrate-resistant acid phosphatase 5b,TRACP-5b ELISA Kit

Code CSB-E08490h
Size 96T,5×96T,10×96T
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name
acid phosphatase 5, tartrate resistant
Alternative Names
phosphatase ELISA Kit; Acid phosphatase 5 tartrate resistant ELISA Kit; Acid phosphatase 5; tartrate resistant ELISA Kit; ACP5 ELISA Kit; EC ELISA Kit; MGC117378 ELISA Kit; PPA5_HUMAN ELISA Kit; serum band 5 tartrate-resistant acid phosphatase ELISA Kit; SPENCDI ELISA Kit; T5ap ELISA Kit; Tartrate resistant acid ATPase ELISA Kit; Tartrate resistant acid phosphatase type 5 ELISA Kit; Tartrate resistant acid phosphatase type 5 precursor ELISA Kit; Tartrate-resistant acid ATPase ELISA Kit; Tartrate-resistant acid phosphatase type 5 ELISA Kit; TR AP ELISA Kit; TR-AP ELISA Kit; TRACP 5 ELISA Kit; TRAP ELISA Kit; TrATPase ELISA Kit; Type 5 acid phosphatase ELISA Kit
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
0.312 mIU/mL-20 mIU/mL
0.078 mIU/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Signal Transduction
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human TRACP-5b in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:1Average %88
Range %83-92
1:2Average %99
Range %94-102
1:4Average %105
Range %100-108
1:8Average %95
Range %90-98
The recovery of human TRACP-5b spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9592-97
EDTA plasma (n=4)9692-99
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
202.484 2.456 2.470 2.357
101.918 1.876 1.897 1.784
51.262 1.251 1.257 1.144
2.50.666 0.715 0.691 0.578
1.250.424 0.454 0.439 0.326
0.6250.312 0.329 0.321 0.208
0.3120.199 0.208 0.204 0.091
00.111 0.115 0.113  
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days

The human TRACP5b ELISA kit (CSB-E08490h) is designed for the quantitative measurement of human TRACP5b protein in serum, plasma, or tissue homogenates. It quantitates human TRACP5b with 0.078 mIU/ml sensitivity and shows excellent specificity for human TRACP5b. It uses the bi-antibody sandwich enzyme immunoassay technique. This assay employs a biotin-conjugated TRACP5b antibody that recognizes the analyte bound by the immobilized TRACP5b antibody, forming an antibody-analyte-antibody complex. The immune complex is further detected by avidin-conjugated HRP. The TMB solution is added into the wells and turns blue and finally turns yellow after the addition of the stop solution. Solution color develops in proportion to the amount of TRACP5b in the sample. The O.D. value is measured using a microplate reader at 450 nm and is used to determine the concentration of the human TRACP5b in the sample.

TRACP5b (ACP5), secreted by osteoclasts, is increased in osteoporosis individuals and is used as a specific and sensitive marker of bone resorption and bone remodeling. After release into circulation, TRACP5b becomes inactive and is degraded into fragments that are removed by the liver. TRACP5b has been applied to diagnose bone diseases such as osteoporosis and bone metastasis and for monitoring antiresorptive treatment. Alatalo et al and Rissanen et al have shown that TRACP5b is a good indicator of osteoclast number in mouse bone marrow-derived osteoclasts and human blood monocyte-derived osteoclasts.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias.
Gene References into Functions
  1. high expression of ACP5 correlates with tumor progression and may serve as a potential prognostic biomarker in lung AD. PMID: 28398694
  2. TRACP-5b level is significantly associated with the OPG level and with the severity and extent of coronary atherosclerosis in coronary artery disease patients PMID: 28428481
  3. Adipokine tartrate-resistant acid phosphatase 5a (TRAP 5a) serum levels correlated positively to anthropometric obesity parameters but not to metabolic syndrome risk factors, indicating that serum TRAP 5a is associated with pathological adipose tissue expansion. PMID: 28532220
  4. TRAP promotes metastasis-related cell properties in MDA-MB-231 breast cancer cells via TGFbeta2/TbetaR and CD44, thereby identifying a potential signaling mechanism associated to TRAP action in breast cancer cells. PMID: 28915803
  5. Serum TRAcP5b activity was associated with density of TRAcP-positive osteoclasts in the subchondral bone of medial tibia plateaux. TRAcP-positive osteoclasts were more abundant in people with symptomatic knee osteoarthritis compared to controls. Serum TRAcP5b activity was associated with baseline pain and pain change. PMID: 28087412
  6. Although serum procollagen type-1 N-terminal propeptide (PINP) levels were not found to be different, tartrate-resistant acid phosphatase type 5b isoform (TRACP 5b) levels were significantly higher in the control group. PMID: 27840329
  7. Nidogen-2, a protein shown to be expressed intracellularly and for secretion by pre-adipocytes, was shown to interact, through its globular G3 domain, with TRAP 5a in vitro. PMID: 25450682
  8. Tartrate-resistant acid phosphatase deficiency in plasmacytoid dendritic cells leads to increased IFNalpha production, providing at least a partial explanation for how ACP5 mutations cause lupus in the context of spondyloenchondrodysplasia. Detection of ACP5 missense variants in a lupus cohort suggests that impaired tartrate-resistant acid phosphatase functioning may increase susceptibility to sporadic lupus PMID: 27390188
  9. Biallelic ACP5 mutations are associated with autoimmune cytopenias. PMID: 27718324
  10. Severe short stature can be the only presenting sign of ACP5 deficiency and the latter could therefore be considered as a rare cause in the differential diagnosis of severe, proportionate growth failure. PMID: 26789720
  11. Spondyloenchondrodysplasia (SPENCD) is a rare autosomal recessive skeletal dysplasia caused by recessive mutations in the ACP5 gene, and it is characterized by the persistence of chondroid tissue islands within the bone. [review] PMID: 26854080
  12. Data show that the levels of serum vascular endothelial growth factor (VEGF) and tartrate resistant acid phosphatase (TRacp-5b) are higher in multiple myeloma with cytogenetic abnormalities. PMID: 27577203
  13. A diverse spectrum of spondyloenchondrodysplasia phenotypes due to mutations in ACP5 has been presented. PMID: 26951490
  14. We identified five new biomarkers: GDF15, osteonectin, TRAP5, TWEAK, and YKL40 as being promising markers for monitoring bone metastases. PMID: 27069189
  15. Trap-5b is overexpressed in renal cell carcinoma patients with bone metastasis and bone resorption. PMID: 27089726
  16. Serum levels of NTx and TRACP5b are sensitive and simple biomarkers to indicate aberrant bone metabolism in giant cell tumor of bone, and they may have a clinical significance in GCT diagnosis. PMID: 26427154
  17. TRACP5a may be a promising chronic inflammatory marker and may play a prognostic role in cancer cachexia. PMID: 25778334
  18. TRACP5b has limited utility as a single marker of metabolic bone disease treatment. PMID: 23737138
  19. Immunohistochemistry revealed that ACP5 expression was positively correlated with FoxM1 expression in human HCC tissues, and their coexpression was associated with poor prognoses PMID: 23604121
  20. Pax6 binds endogenously to the proximal region of the tartrate acid phosphatase (TRAP) gene promoter and suppresses nuclear factor of activated T cells c1 (NFATc1)-induced TRAP gene expression. PMID: 23990468
  21. TRAP is a novel human adipokine produced by macrophages and secreted from the subcutaneous adipose tissue in vivo and in vitro. TRAP is involved in fat accumulation and adipose inflammation. PMID: 21386798
  22. The ACP5 gene is neither associated with the occurrence nor the curve severity of adolescent idiopathic scoliosis. PMID: 22490295
  23. The results showed that both OC and TRACP-5b values were at their highest during the ovulation period, and the activity of TRACP-5b was more significant than that of OC. Furthermore, the changes in sex hormone secretion involved in OC and TRACP-5b showed specific patterns during the menstrual cycle. PMID: 22517558
  24. Tartrate-resistant acid phosphatase stain-ing of bone marrow osteoclasts cannot serve as a tool to determine the time of death of a patient. PMID: 22844067
  25. Serum TRACP5a is a macrophage-derived inflammation marker associated with CVD risk PMID: 21300043
  26. Data from studies in relatively young, postmenopausal women suggest that serum level of TRAP 5b (a marker of bone resorption) can be lowered by dietary factors (i.e., low-fat vitamin D- and calcium-fortified cheese). PMID: 22357739
  27. TRAcP 5b could be useful as a diagnostic tool for the detection of bone metastases in patients with breast cancer. PMID: 22335021
  28. osteopontin is regulated by TRAP in the pathogenesis of common autoimmune disorders PMID: 21217752
  29. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature PMID: 21217755
  30. Serum TRACP5b activity test is a potentially useful adjunct in diagnosing and monitoring bone metastasis in non-small cell lung cancer PMID: 20932965
  31. The presence of TRAP-positive macrophages in bone metastases could, together with cancer cells and osteoclasts, contribute to the elevated levels of serum TRAP activity observed in patients with bone metastases. PMID: 20967488
  32. TRACP 5b activity and its interval change after treatment bore a prognostic role in breast cancer patients with bone metastasis and a high baseline serum TRACP 5b activity. PMID: 20416078
  33. Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. PMID: 11983200
  34. One isoenzyme, but not the other (5b but not 5a) correlates with other markers of bone turnover and bone mineral density. PMID: 12073156
  35. serum tartrate resistant tartrate resistant acid phosphatase 5 is useful as a marker for bone resorption PMID: 12589973
  36. specific and sensitive marker of bone resorption and for the early detection of the spreading of breast cancer cells to bone PMID: 12820342
  37. Increased tartrate-resistant acid phosphatase isoform 5b is associated with multiple myeloma bone disease PMID: 12845688
  38. In human serum, TRACP 5b circulates in a large complex that contained alpha2M and calcium. PMID: 12901871
  39. The Human serum tartrate-resistant acid phosphatase exists as two enzyme isoforms (TRACP 5a and 5b), derived by differential, post-translational processing of a common gene product. PMID: 15542543
  40. Elevated tartrate-resistant acid phosphatase 5b in serum is associted with extensive bone metastasis in breast cancer PMID: 15701839
  41. Results lead to hypothesize that the capacity of osteoblast-like cells to endocytose TRACP (ACP5) is important for the removal of this enzyme during or following the bone resorptive activity of the osteoclast. PMID: 15878315
  42. a role of the loop residue D158 in catalysis in the cleaved enzyme. PMID: 15950921
  43. crystal structures at 2.2A resolution demonstrate that the repression loop exhibits significant conformational flexibility, and the observed alternate binding mode suggests a possible inhibitory role for this loop (purple Acid phosphatase) PMID: 15993892
  44. The results suggest that in endothelial cells of the afferent arterioles, mesangial cells, and lymphocytes the cellular activities are regulated by high constitutive phosphotyrosine phosphatase. PMID: 16200454
  45. the MCP-1-induced TRAP(+)/CTR(+) multinuclear cells represent an arrested stage in osteoclast differentiation, after NFATc1 induction and cellular fusion but prior to the development of bone resorption activity PMID: 16280328
  46. These results suggest that the protease-sensitive loop peptide, redox-active iron, and disulfide bond are important regulatory sites in TRACP. PMID: 16620768
  47. TRAP might be useful as a marker of progression of malignant disease and could be a potential target for cancer therapies. PMID: 16869970
  48. This work suggests that tumour derived TRAP contributes to the raised enzyme activity found in the serum of breast cancer patients. PMID: 17088078
  49. TRAP 5b may serve as a new additional marker of bone resorption in the assessment of renal osteodystrophy. PMID: 17357281
  50. heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts PMID: 17997709

Show More

Hide All

Involvement in disease
Spondyloenchondrodysplasia with immune dysregulation (SPENCDI)
Subcellular Location
Protein Families
Metallophosphoesterase superfamily, Purple acid phosphatase family
Database Links

HGNC: 124

OMIM: 171640

KEGG: hsa:54

STRING: 9606.ENSP00000218758

UniGene: Hs.1211

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St Ste 610-322 Houston, TX 77054, USA
Join Us with

Leave a message

check code
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1